Threshold Pharmaceuticals, Inc. Presents TH-302 Preclinical Results in Three Scientific Presentations at American Association for Cancer Research Annual Meeting

REDWOOD CITY, Calif., April 20, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced multiple preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research (AACR) Annual Meeting, being held April 17 to 21, 2010, in Washington, D.C.